A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status

DOI: 10.1158/1055-9965.EPI-18-0510 Published October 2018

Online Impact

Volume 27, Issue 10, pp. 1231-1233

DOI

PubMed

Published By

Print ISSN

Online ISSN

History

Konrad H. Stopsack1,2,*,
Amparo G. Gonzalez-Feliciano2,
Samuel F. Peisch2,
Mary K. Downer2,3,
Riley A. Gage2,
Stephen Finn4,5,
Rosina T. Lis6,
Rebecca E. Graff2,7,
Andreas Pettersson2,8,
Claire H. Pernar2,
Massimo Loda4,
Philip W. Kantoff1,
Thomas U. Ahearn9, and
Lorelei A. Mucci2,3; on behalf of the Transdisciplinary Prostate Cancer Partnership (ToPCaP)

¹Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
²Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
³Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
⁴Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
⁵Department of Pathology, Trinity College Dublin, Dublin, Ireland.
⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
⁷Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
⁸Department of Medicine, Clinical Epidemiology Unit, Solna, Karolinska Institutet, Stockholm, Sweden.
⁹National Cancer Institute, Division of Cancer Epidemiology and Genetics, Epidemiology and Biostatistics Program, Bethesda, Maryland.

↵*Corresponding Author:
Konrad H. Stopsack, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Phone: 857-891-2637; E-mail: stopsack{at}mskcc.org